ENSG Stock Analysis: The Ensign | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 10.664m USD | 12M Return: 9.6% | US29358P1012 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 74.0M
EPS Trend: 99.3%
Qual. Beats: 1
Rev. Trend: 99.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Ensign Group, Inc. (ENSG) is a U.S. healthcare services company that provides skilled nursing, senior living, and rehabilitative care, operating through two segments. The Skilled Services segment delivers short- and long-term nursing care, specialty services such as on-site dialysis, ventilator care, and cardiac/pulmonary management, as well as standard room, board, and social services. The Standard Bearer segment acts as a real estate arm that leases post-acute care properties to affiliated and third-party healthcare operators, allowing Ensign to separate facility ownership from clinical operations. The company also runs senior living units and offers ancillary services including mobile diagnostics, in-facility pharmacy, respiratory therapy, and patient transportation.
Ensign operates facilities across 16 states, primarily in the western and southern U.S., and is headquartered in San Juan Capistrano, California. The split between operating companies and property-holding entities is a common structure in the post-acute and long-term care industry, where healthcare REITs and operators frequently segregate real estate assets from clinical operations to optimize capital efficiency and tax treatment. The skilled nursing and senior living sectors serve an aging population requiring chronic and post-hospitalization care, a demographic that has driven consistent demand for these services across the U.S.
- Skilled nursing occupancy and Medicare reimbursement updates
- Acquisition pace of distressed facilities drives footprint expansion
- Labor cost inflation pressures nursing home operating margins
| Net Income: 378.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.68 > 1.0 |
| NWC/Revenue: 3.40% < 20% (prev 6.75%; Δ -3.35% < -1%) |
| CFO/TA 0.11 > 3% & CFO 608.4m > Net Income 378.7m |
| Net Debt (4.04b) to EBITDA (621.3m): 6.50 < 3 |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.5m) vs 12m ago 1.50% < -2% |
| Gross Margin: 14.14% > 18% (prev 15.88%; Δ -1.74% > 0.5%) |
| Asset Turnover: 102.8% > 50% (prev 93.60%; Δ 9.15% > 0%) |
| Interest Coverage Ratio: 65.04 > 6 (EBIT TTM 506.7m / Interest Expense TTM 7.79m) |
| A: 0.03 (Total Current Assets 1.07b - Total Current Liabilities 884.8m) / Total Assets 5.75b |
| B: 0.34 (Retained Earnings 1.95b / Total Assets 5.75b) |
| C: 0.09 (EBIT TTM 506.7m / Avg Total Assets 5.34b) |
| D: 0.74 (Book Value of Equity 2.44b / Total Liabilities 3.30b) |
| Altman-Z'' = 2.73 = A |
| DSRI: 0.97 (Receivables 668.9m/578.0m, Revenue 5.49b/4.61b) |
| GMI: 1.12 (GM 15.88% / 14.14%) |
| AQI: 0.94 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 1.19 (Revenue 5.49b / 4.61b) |
| TATA: -0.04 (NI 378.7m - CFO 608.4m) / TA 5.75b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of August 14, 2026, the stock is trading at USD 181.88 with a total of 405,154 shares traded. Over the past week, the price has changed by +0.12%, over one month by +8.01%, over three months by +2.22% and over the past year by +9.55%.
Current recommended Stop Loss: 169.00 (which is 7.1% or 2.7 ATR below the current price).
The Ensign has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy ENSG.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 220 | 21% |
P/E Trailing = 28.6338
P/E Forward = 23.6967
P/S = 1.9436
P/B = 4.3674
P/EG = 1.578
Revenue TTM = 5.49b USD
EBIT TTM = 506.7m USD
EBITDA TTM = 621.3m USD
Long Term Debt = 135.6m USD (from longTermDebt, last quarter)
Short Term Debt = 125.3m USD (from shortTermDebt, last quarter)
Debt = 4.36b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.11b
Net Debt = 4.04b USD (calculated: Debt 4.36b - CCE 320.8m)
Enterprise Value = 14.7b USD (10.7b + Debt 4.36b - CCE 320.8m)
Interest Coverage Ratio = 65.04 (Ebit TTM 506.7m / Interest Expense TTM 7.79m)
EV/FCF = 35.09x (Enterprise Value 14.7b / FCF TTM 419.1m)
FCF Yield = 2.85% (FCF TTM 419.1m / Enterprise Value 14.7b)
FCF Margin = 7.64% (FCF TTM 419.1m / Revenue TTM 5.49b)
Net Margin = 6.90% (Net Income TTM 378.7m / Revenue TTM 5.49b)
Gross Margin = 14.14% ((Revenue TTM 5.49b - Cost of Revenue TTM 4.71b) / Revenue TTM)
Gross Margin QoQ = 16.65% (prev 16.40%)
Tobins Q-Ratio = 2.56 (Enterprise Value 14.7b / Total Assets 5.75b)
Interest Expense / Debt = 0.18% (Interest Expense 7.79m / Debt 4.36b)
Taxrate = 24.03% (119.9m / 498.9m)
NOPAT = 385.0m (EBIT 506.7m * (1 - 24.03%))
Current Ratio = 1.21 (Total Current Assets 1.07b / Total Current Liabilities 884.8m)
Debt / Equity = 1.79 (Debt 4.36b / totalStockholderEquity, last quarter 2.44b)
Debt / EBITDA = 6.50 (Net Debt 4.04b / EBITDA 621.3m)
Debt / FCF = 9.64 (Net Debt 4.04b / FCF TTM 419.1m)
Total Stockholder Equity = 2.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 378.7m / Total Assets 5.75b)
RoE = 16.53% (Net Income TTM 378.7m / Total Stockholder Equity 2.29b)
RoCE = 20.89% (EBIT 506.7m / Capital Employed (Equity 2.29b + L.T.Debt 135.6m))
RoIC = 8.16% (NOPAT 385.0m / Invested Capital 4.72b)
WACC = 4.75% (E(10.7b)/V(15.0b) * Re(6.63%) + D(4.36b)/V(15.0b) * Rd(0.18%) * (1-Tc(0.24)))
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.02 | Cagr: 1.19%
[DCF] Terminal Value 77.97% ; FCFF base≈362.2m ; Y1≈415.2m ; Y5≈611.0m
[DCF] Fair Price = 88.44 (EV 9.19b - Net Debt 4.04b = Equity 5.15b / Shares 58.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.35 | EPS CAGR: 16.70% | SUE: 1.67 | # QB: 1
Revenue Correlation: 99.82 | Revenue CAGR: 16.89% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.96 | Chg30d=+2.98% | Revisions=+38% | Analysts=5
EPS current Year (2026-12-31): EPS=7.79 | Chg30d=+3.13% | Revisions=+62% | GrowthEPS=+18.6% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=8.55 | Chg30d=+2.67% | Revisions=+62% | GrowthEPS=+9.7% | GrowthRev=+10.2%
[Analyst] Revisions Ratio: +72% (up=14, down=1)